A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Daehwa Pharmaceutical Co., Ltd.
Orano Med LLC
Bayer
Sunnybrook Health Sciences Centre
The Methodist Hospital Research Institute
Turku University Hospital
Institut Jean-Godinot
Pfizer
OncoTherapy Science, Inc.
Pfizer
CSPC Megalith Biopharmaceutical Co.,Ltd.
General Oncology, Inc.
DualityBio Inc.
OncoNano Medicine, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Ono Pharmaceutical Co. Ltd
Lyell Immunopharma, Inc.
University College, London
Esperas Pharma Inc.
MacroGenics
Stanford University
Dana-Farber Cancer Institute
Mundipharma Research Limited
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
National Cancer Institute (NCI)
Peter MacCallum Cancer Centre, Australia
Daehwa Pharmaceutical Co., Ltd.
Leap Therapeutics, Inc.
Pfizer
Gangnam Severance Hospital
Nektar Therapeutics
Kiadis Pharma
GBG Forschungs GmbH
British Columbia Cancer Agency
MedSIR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NKGen Biotech, Inc.
Dana-Farber Cancer Institute
Incyte Corporation
Jonsson Comprehensive Cancer Center
Centre Leon Berard
Southwest Hospital, China
Rexahn Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Mayo Clinic
Sun Pharma Advanced Research Company Limited
Liaoning Cancer Hospital & Institute